|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
ATE151467T1
(de)
|
1987-11-30 |
1997-04-15 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
|
JPH03503894A
(ja)
|
1988-03-25 |
1991-08-29 |
ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション |
オリゴヌクレオチド ｎ‐アルキルホスホラミデート
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
ES2116977T3
(es)
|
1990-05-11 |
1998-08-01 |
Microprobe Corp |
Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
|
|
GB9011454D0
(en)
*
|
1990-05-22 |
1990-07-11 |
Medical Res Council |
Polynucleotide amplification
|
|
AU8284991A
(en)
|
1990-06-29 |
1992-01-23 |
Regents Of The University Of Michigan, The |
Neurofibromatosis gene
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
MY107332A
(en)
|
1990-08-03 |
1995-11-30 |
Sterling Drug Inc |
Compounds and methods for inhibiting gene expression.
|
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
JPH06505704A
(ja)
|
1990-09-20 |
1994-06-30 |
ギリアド サイエンシズ，インコーポレイテッド |
改変ヌクレオシド間結合
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
KR930702373A
(ko)
|
1990-11-08 |
1993-09-08 |
안토니 제이. 페이네 |
합성 올리고누클레오티드에 대한 다중 리포터(Reporter)그룹의 첨합
|
|
US5510473A
(en)
|
1990-11-09 |
1996-04-23 |
The United States Of American As Represented By The Secretary Of Health And Human Services |
Cloning of the recA gene from thermus aquaticus YT-1
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
DE69233046T2
(de)
|
1991-10-24 |
2004-03-04 |
Isis Pharmaceuticals, Inc., Carlsfeld |
Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
|
GB9206016D0
(en)
|
1992-03-19 |
1992-04-29 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
|
EP0646178A1
(en)
|
1992-06-04 |
1995-04-05 |
The Regents Of The University Of California |
expression cassette with regularoty regions functional in the mammmlian host
|
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
HU219767B
(hu)
|
1993-01-26 |
2001-07-30 |
Leslie R. Coney |
Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
HU9501974D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
DE733059T1
(de)
|
1993-12-09 |
1997-08-28 |
Univ Jefferson |
Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5962428A
(en)
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
CA2263784A1
(en)
|
1998-03-23 |
1999-09-23 |
Megabios Corporation |
Dual-tagged proteins and their uses
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
US7053207B2
(en)
|
1999-05-04 |
2006-05-30 |
Exiqon A/S |
L-ribo-LNA analogues
|
|
US20040192593A1
(en)
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
US20020006397A1
(en)
|
2000-04-28 |
2002-01-17 |
Roberts Bruce L. |
In VIVO loading of MHC
|
|
ATE353361T1
(de)
|
2000-04-28 |
2007-02-15 |
Sangamo Biosciences Inc |
Gezielten modifikation der chromatinstruktur
|
|
ATE318923T1
(de)
|
2000-06-01 |
2006-03-15 |
Univ North Carolina |
Doppelsträngige parvovirus-vektoren
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
JP2005500061A
(ja)
|
2001-08-20 |
2005-01-06 |
ザ スクリップス リサーチ インスティテュート |
Ｃｎｎについての亜鉛フィンガー結合ドメイン
|
|
CA2459347C
(en)
|
2001-09-04 |
2012-10-09 |
Exiqon A/S |
Locked nucleic acid (lna) compositions and uses thereof
|
|
WO2003072788A1
(en)
|
2002-02-21 |
2003-09-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
US7449561B1
(en)
|
2002-02-26 |
2008-11-11 |
City Of Hope |
Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
MXPA05004860A
(es)
|
2002-11-04 |
2005-08-18 |
Advisys Inc |
Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas.
|
|
US20070185042A1
(en)
|
2003-08-08 |
2007-08-09 |
The Brigham And Women's Hospital, Inc. President And Fellows Of Harvard College |
Sirna based methods for treating alzheimer's disease
|
|
EP1678315B1
(en)
|
2003-09-19 |
2011-08-03 |
Sangamo BioSciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
CN101267805A
(zh)
|
2005-07-27 |
2008-09-17 |
普洛体维生物治疗公司 |
制造脂质体的系统和方法
|
|
EP1922405A4
(en)
|
2005-08-05 |
2009-04-01 |
Univ Michigan State |
GENE FROM ACTINOBACILLUS SUCCINOGENES 13OZ (ATCC 55618) FOR THE MANUFACTURE OF CHEMICALS FROM THE A. SUCCINOGENES C4 PATH
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
US8685687B2
(en)
|
2006-07-05 |
2014-04-01 |
The Scripps Research Institute |
Chimeric zinc finger recombinases optimized for catalysis by directed evolution
|
|
WO2008070859A2
(en)
|
2006-12-07 |
2008-06-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Treatment of skin conditions by dickkopf1 (dkk1)
|
|
WO2008073303A2
(en)
|
2006-12-07 |
2008-06-19 |
Switchgear Genomics |
Transcriptional regulatory elements of biological pathways, tools, and methods
|
|
WO2008086807A2
(en)
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
|
WO2008151631A2
(en)
|
2007-06-15 |
2008-12-18 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
US20100076057A1
(en)
|
2008-09-23 |
2010-03-25 |
Northwestern University |
TARGET DNA INTERFERENCE WITH crRNA
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
ES2560281T3
(es)
|
2008-10-17 |
2016-02-18 |
Joule Unlimited Technologies, Inc. |
Producción de etanol por microorganismos
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
WO2010075424A2
(en)
|
2008-12-22 |
2010-07-01 |
The Regents Of University Of California |
Compositions and methods for downregulating prokaryotic genes
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
EP2480659A2
(en)
|
2009-09-24 |
2012-08-01 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
KR101874463B1
(ko)
|
2009-10-31 |
2018-08-02 |
뉴 월드 레보러토리즈 인코포레이티드. |
세포의 재프로그램화 방법 및 이의 용도
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
EP2533629B1
(en)
|
2010-02-11 |
2018-11-28 |
Recombinetics, Inc. |
Methods and materials for producing transgenic artiodactyls
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
EP2517731A1
(en)
|
2011-04-07 |
2012-10-31 |
Ludwig-Maximilians-Universität München |
Method of activating a target gene in a cell
|
|
EP2729567B1
(en)
|
2011-07-08 |
2016-10-05 |
Cellectis |
Method for increasing the efficiency of double-strand break-induced mutagenssis
|
|
HK1200871A1
(en)
|
2011-11-16 |
2015-08-14 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013152220A2
(en)
|
2012-04-04 |
2013-10-10 |
Life Technologies Corporation |
Tal-effector assembly platform, customized services, kits and assays
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
US9738879B2
(en)
|
2012-04-27 |
2017-08-22 |
Duke University |
Genetic correction of mutated genes
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
AU2013293270B2
(en)
|
2012-07-25 |
2018-08-16 |
Massachusetts Institute Of Technology |
Inducible DNA binding proteins and genome perturbation tools and applications thereof
|
|
US9567581B2
(en)
|
2012-08-07 |
2017-02-14 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive X chromosome
|
|
EP3789405A1
(en)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
KR102121086B1
(ko)
|
2012-11-01 |
2020-06-09 |
팩터 바이오사이언스 인크. |
세포에서 단백질을 발현시키는 방법들과 생성물들
|
|
US20140140969A1
(en)
|
2012-11-20 |
2014-05-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for muscular dystrophies
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
WO2014093479A1
(en)
|
2012-12-11 |
2014-06-19 |
Montana State University |
Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
IL239344B2
(en)
|
2012-12-12 |
2024-06-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
WO2014145838A2
(en)
|
2013-03-15 |
2014-09-18 |
Britt Edward J |
Energy conversion device and method for making and using same
|
|
US20140329762A1
(en)
*
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
|
SG10201913068PA
(en)
|
2013-06-04 |
2020-02-27 |
Harvard College |
Rna-guided transcriptional regulation
|
|
WO2014197748A2
(en)
*
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US10265347B2
(en)
|
2013-08-29 |
2019-04-23 |
Norimasa Miura |
Biomolecular group related to cell anti-aging
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
WO2015089427A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
JP2017509322A
(ja)
|
2014-01-29 |
2017-04-06 |
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） |
分化細胞の分化転換
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
JP2017512481A
(ja)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ |
Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
|
|
WO2015161276A2
(en)
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
ES2788426T3
(es)
|
2014-06-16 |
2020-10-21 |
Univ Johns Hopkins |
Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1
|
|
CA2954791C
(en)
|
2014-07-14 |
2025-11-18 |
The Regents Of The University Of California |
CRISPR/CAS TRANSCRIPTIONAL MODULATION
|
|
US20170219596A1
(en)
|
2014-07-14 |
2017-08-03 |
The Regents Of The University Of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
|
WO2016022866A1
(en)
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
|
CN106714845A
(zh)
|
2014-08-11 |
2017-05-24 |
得克萨斯州大学系统董事会 |
通过crispr/cas9介导的基因编辑预防肌营养不良
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
MA40880A
(fr)
|
2014-10-30 |
2017-09-05 |
Temple Univ Of The Commonwealth |
Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
|
|
US11319555B2
(en)
|
2014-11-20 |
2022-05-03 |
Duke University |
Compositions, systems and methods for cell therapy
|
|
KR102531016B1
(ko)
|
2014-11-21 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US10190106B2
(en)
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
US20160281166A1
(en)
|
2015-03-23 |
2016-09-29 |
Parabase Genomics, Inc. |
Methods and systems for screening diseases in subjects
|
|
EP3748004A1
(en)
|
2015-04-01 |
2020-12-09 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
US20180305689A1
(en)
|
2015-04-22 |
2018-10-25 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
|
|
WO2016187717A1
(en)
|
2015-05-26 |
2016-12-01 |
Exerkine Corporation |
Exosomes useful for genome editing
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
PE20181145A1
(es)
|
2015-07-24 |
2018-07-17 |
Basf Se |
Compuestos de piridina
|
|
US20200123533A1
(en)
|
2015-07-31 |
2020-04-23 |
The Trustees Of Columbia University In The City Of New York |
High-throughput strategy for dissecting mammalian genetic interactions
|
|
WO2017035416A2
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
EP3350315A4
(en)
|
2015-09-18 |
2019-07-17 |
The Regents of The University of California |
METHOD FOR THE AUTOCATALYTIC GENOMIC PROCESSING AND NEUTRALIZATION OF AUTO CATALYTIC GENOMIC PROCESSING AND COMPOSITIONS THEREFOR
|
|
WO2017049407A1
(en)
|
2015-09-23 |
2017-03-30 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
AU2016344609B2
(en)
|
2015-10-28 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of duchenne muscular dystrophy
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
EP3374501B1
(en)
|
2015-11-11 |
2023-07-12 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
|
WO2017083766A1
(en)
|
2015-11-13 |
2017-05-18 |
Massachusetts Institute Of Technology |
High-throughput crispr-based library screening
|
|
KR102787119B1
(ko)
*
|
2015-11-30 |
2025-03-27 |
듀크 유니버시티 |
유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
|
|
IL260532B2
(en)
|
2016-01-11 |
2023-12-01 |
Univ Leland Stanford Junior |
Chimeric proteins- containing systems and uses thereof in regulating gene expression
|
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
|
WO2017139505A2
(en)
|
2016-02-11 |
2017-08-17 |
The Regents Of The University Of California |
Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
|
|
WO2017165859A1
(en)
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
SG11201808812RA
(en)
|
2016-04-15 |
2018-11-29 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
|
LT3442600T
(lt)
|
2016-04-15 |
2024-05-27 |
Research Institute At Nationwide Children's Hospital |
Su adeno virusu susijusio viruso vektoriaus iš β-sarkoglikano ir mikro- rnr-29 pristatymas ir raumenų distrofijos gydymas
|
|
JP7075597B2
(ja)
*
|
2016-05-05 |
2022-05-26 |
デューク ユニバーシティ |
デュシェンヌ型筋ジストロフィーを治療するためのｃｒｉｓｐｒ／ｃａｓ関連の方法および組成物
|
|
US11278550B2
(en)
|
2016-05-17 |
2022-03-22 |
Duke University |
Compositions and methods for the treatment of Prader-Willi syndrome
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
JP2019525742A
(ja)
|
2016-06-30 |
2019-09-12 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマー
|
|
EP4321623A3
(en)
|
2016-07-15 |
2024-05-15 |
Salk Institute for Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
CN109715218A
(zh)
|
2016-07-18 |
2019-05-03 |
嘉安生物治疗有限责任公司 |
用于治疗心脏疾病的组合物和方法
|
|
WO2018017751A1
(en)
|
2016-07-19 |
2018-01-25 |
Supereye, Inc. |
Systems and methods for predictive visual rendering
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
SG11201901306XA
(en)
|
2016-08-19 |
2019-03-28 |
Toolgen Inc |
Artificially engineered angiogenesis regulatory system
|
|
CA3034369A1
(en)
|
2016-08-19 |
2018-02-22 |
Whitehead Institute For Biomedical Research |
Methods of editing dna methylation
|
|
JP2019524149A
(ja)
|
2016-08-20 |
2019-09-05 |
アベリノ ラボ ユーエスエー インコーポレイテッドＡｖｅｌｌｉｎｏ Ｌａｂ ＵＳＡ， Ｉｎｃ． |
一本鎖ガイドＲＮＡ、ＣＲＩＳＰＲ／Ｃａｓ９システム、及びそれらの使用方法
|
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018081504A1
(en)
|
2016-10-28 |
2018-05-03 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
|
AU2017364106A1
(en)
|
2016-11-28 |
2019-06-20 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing
|
|
CA3045335A1
(en)
|
2016-12-01 |
2018-06-07 |
Universite Laval |
Crispr-based treatment of friedreich ataxia
|
|
WO2018107003A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
US11136555B2
(en)
|
2017-03-01 |
2021-10-05 |
Elixirgen Scientific, Inc. |
Compositions and methods for differentiation of human pluripotent stem cells into desired cell types
|
|
US20210322577A1
(en)
|
2017-03-03 |
2021-10-21 |
Flagship Pioneering Innovations V, Inc. |
Methods and systems for modifying dna
|
|
US10687520B2
(en)
|
2017-03-07 |
2020-06-23 |
The Board Of Regents Of The University Of Texas System |
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
|
|
WO2018162702A1
(en)
|
2017-03-10 |
2018-09-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
|
CN116392609A
(zh)
|
2017-03-23 |
2023-07-07 |
Dnarx公司 |
用于体内核酸表达的系统和方法
|
|
EP3617311B1
(en)
|
2017-03-30 |
2024-11-20 |
Kyoto University |
Method for inducing exon skipping by genome editing
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
US20180305719A1
(en)
|
2017-04-19 |
2018-10-25 |
The Board Of Trustees Of The University Of Illinois |
Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
|
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
EP3420811A1
(en)
|
2017-06-29 |
2019-01-02 |
Paris Sciences et Lettres - Quartier Latin |
Non-human model for neurofibromatosis type 1
|
|
SG11201913852RA
(en)
|
2017-07-07 |
2020-01-30 |
Toolgen Inc |
Target-specific crispr mutant
|
|
WO2019014122A1
(en)
|
2017-07-08 |
2019-01-17 |
The Brigham And Women's Hospital, Inc. |
METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY
|
|
EP3712272A4
(en)
|
2017-07-25 |
2021-10-13 |
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences |
METHOD FOR MODULATION OF RNA SPLICE BY INDUCTION OF A BASE MUTATION AT THE SPLICE POINT OR A BASE SUBSTITUTION IN THE POLYPYRIMIDINE REGION
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
US20200260698A1
(en)
|
2017-08-18 |
2020-08-20 |
The Board Of Regents Of The University Of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
|
EP3675836A4
(en)
|
2017-08-31 |
2021-05-26 |
Sarepta Therapeutics, Inc. |
METHODS FOR TREATING MUSCLE DYSTROPHY
|
|
US11779653B2
(en)
|
2017-09-29 |
2023-10-10 |
The Regents Of The University Of California |
Multi-armed polyrotaxane platform for protected nucleic acid delivery
|
|
US11987790B2
(en)
|
2017-10-17 |
2024-05-21 |
Massachusetts Institute Of Technology |
Methods for high-resolution genome-wide functional dissection of transcriptional regulatory regions
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
HUE070436T2
(hu)
|
2017-10-23 |
2025-06-28 |
Stoke Therapeutics Inc |
Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére
|
|
EP3707155A2
(en)
|
2017-11-09 |
2020-09-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas systems for treatment of dmd
|
|
EP3720508A4
(en)
|
2017-12-08 |
2021-09-01 |
University of Connecticut |
COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS
|
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
|
|
EP3728589A4
(en)
|
2017-12-22 |
2021-11-03 |
G+Flas Life Sciences |
CHEMICAL GENOMIC ENGINEERING MOLECULES AND PROCESSES
|
|
EP3733844B1
(en)
|
2017-12-28 |
2025-04-02 |
Kyoto University |
Composition for modifying target gene
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
WO2019165168A1
(en)
|
2018-02-23 |
2019-08-29 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
WO2019204750A1
(en)
|
2018-04-20 |
2019-10-24 |
Cellino Biotech, Inc. |
Directed cell fate specification and targeted maturation
|
|
WO2019213626A1
(en)
|
2018-05-03 |
2019-11-07 |
President And Fellows Of Harvard College |
In vivo homology directed repair in heart, skeletal muscle, and muscle stem cells
|
|
US20210299174A1
(en)
|
2018-05-30 |
2021-09-30 |
M2X2 Therapeutics, Inc. |
Cell therapy
|
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
|
US12508325B2
(en)
|
2018-12-20 |
2025-12-30 |
Ohio State Innovation Foundation |
Compositions and methods for reprogramming diseased musculoskeletal cells
|
|
BR102019009665A2
(pt)
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
CA3128755C
(en)
|
2019-02-13 |
2024-06-04 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
JP2022526669A
(ja)
|
2019-04-12 |
2022-05-25 |
デューク ユニバーシティ |
ジストロフィン機能を修復するためのＣＲＩＳＰＲ／Ｃａｓをベースにした塩基編集組成物
|
|
AR118668A1
(es)
|
2019-04-14 |
2021-10-20 |
Univ Duke |
Composiciones para editar genoma a base de crispr / cas para restaurar la función de distrofina
|
|
WO2020214609A1
(en)
|
2019-04-14 |
2020-10-22 |
Duke University |
Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
|
|
JP2022537551A
(ja)
|
2019-06-20 |
2022-08-26 |
セルジーン・クオンティセル・リサーチ・インコーポレイテッド |
ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
|
|
EP4010485A4
(en)
|
2019-08-08 |
2023-08-23 |
Duke University |
HIGH-THROUGHPUT SCREENING PLATFORM FOR NEXT-GENERATION GENE THERAPY VECTOR ENGINEERING
|
|
JP2022545462A
(ja)
|
2019-08-19 |
2022-10-27 |
デューク ユニバーシティ |
Ｃｒｉｓｐｒ／ｃａｓ９ベースの転写活性化因子による骨格筋芽細胞前駆細胞系譜特定
|
|
US20220307015A1
(en)
|
2019-08-19 |
2022-09-29 |
Duke University |
Compositions and methods for identifying regulators of cell type fate specification
|
|
EP4031147A4
(en)
|
2019-09-20 |
2024-10-02 |
The UAB Research Foundation |
Methods of treatment of neurofibromatosis type 1 (nf1) and nf1-mediated conditions and compositions for use in such methods
|
|
US20220364124A1
(en)
|
2019-10-02 |
2022-11-17 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
|
EP4069314A4
(en)
|
2019-12-03 |
2024-06-26 |
Duke University |
SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
|
|
EP4126224A4
(en)
|
2020-04-27 |
2024-07-03 |
Duke University |
HIGH-THROUGHPUT SCREENING METHODS TO DISCOVER OPTIMAL GRNA PAIRS FOR CRISPR-MEDIATED EXON DELETION
|
|
WO2021222328A1
(en)
|
2020-04-27 |
2021-11-04 |
Duke University |
Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
|
|
EP4125349A4
(en)
|
2020-04-27 |
2024-07-10 |
Duke University |
GENE EDITING OF SATELLITE CELLS IN VIVO USING AAV VECTORS ENCODING MUSCLE-SPECIFIC PROMOTERS
|
|
EP4200406A1
(en)
|
2020-08-21 |
2023-06-28 |
Julius-Maximilians-Universität Würzburg |
Modified lymphocytes
|
|
US20230383297A1
(en)
|
2020-10-09 |
2023-11-30 |
Duke University |
Novel targets for reactivation of prader-willi syndrome-associated genes
|
|
EP4225907A4
(en)
|
2020-10-12 |
2025-01-22 |
Duke University |
CRISPR/CAS-BASED BASE EDITING COMPOSITION TO RESTORE DYSTROPHIN FUNCTION
|
|
WO2022087321A1
(en)
|
2020-10-21 |
2022-04-28 |
Duke University |
Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
|
|
CA3198105A1
(en)
|
2020-11-11 |
2022-05-19 |
X. Shawn Liu |
Multiplex epigenome editing
|
|
WO2022104159A1
(en)
|
2020-11-13 |
2022-05-19 |
Duke University |
Targeted gene regulation of human immune cells with crispr-cas systems
|
|
WO2022133062A1
(en)
|
2020-12-16 |
2022-06-23 |
Epicrispr Biotechnologies, Inc. |
Systems and methods for engineering characteristics of a cell
|
|
WO2022187288A2
(en)
|
2021-03-01 |
2022-09-09 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20240058425A1
(en)
|
2022-03-08 |
2024-02-22 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
WO2023200998A2
(en)
|
2022-04-13 |
2023-10-19 |
Duke University |
Effector domains for crispr-cas systems
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
US20260053950A1
(en)
|
2022-08-18 |
2026-02-26 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
|
KR20250077608A
(ko)
|
2022-08-19 |
2025-05-30 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024081937A2
(en)
|
2022-10-13 |
2024-04-18 |
Duke University |
Cas12a fusion proteins and methods of using same
|